Lympha™ · Daily Lymphatic Tincture

Feel lighter. Less puffy. More like yourself.

When fluid seems to linger after sleep, travel, or long days sitting or standing, Lympha supports lymphatic flow, microcirculation, and healthy fluid balance.*

5 named actives — zero proprietary blends
1,075mg fully disclosed actives per daily serving
3 connected circulatory functions*

Alcohol-free
Preservative-free
Vegan
30 servings

“I’m on day 18 and my face looks less swollen around my eyes and jaw. I’m not someone who normally sticks with supplements but I'm still taking this one.”
— Elizabeth, verified buyer ★★★★★

30-Day Satisfaction Guarantee

Experience Lympha with confidence. If it is not the right fit for you, contact us within 30 days of delivery. View guarantee details

Five named, disclosed actives· Dosed at clinically studied levels· Standardized extracts· Made in USA· GMP-certified

If this sounds like your body lately

You're not imagining it. Some days, your body feels slower to reset.

Lympha was made for the everyday shifts that can follow travel, long periods of sitting or standing, poor sleep, hormonal fluctuations, and the way circulation and fluid balance naturally evolve with age.*

Puffy mornings

You go to bed feeling like yourself and wake up noticeably puffier.

Desk days, travel days

Hours sitting at a desk, in a car, or on a plane can leave your body feeling heavy, tight, or less comfortable.

Heavier by evening

You start the day feeling like yourself, then notice more puffiness, heaviness, or tightness by evening.

Between bodywork sessions

You want consistent daily support between massage, lymphatic work, compression, sauna, or movement.

This isn’t a sign you’re doing anything wrong — it may simply mean the systems behind healthy fluid balance need more daily support than they used to.*

See the systems behind healthy fluid balance

A bottle of Lympha on a counter beside a glass of water in morning light

In their words

“My chiropractor recommended this after I mentioned the swelling I get in my lower legs and ankles. I've definitely noticed a difference since starting it.”

Jane C. Verified buyer

Read all verified reviews

A System-Level Formula

Three connected circulatory functions behind healthy fluid balance.

Together, venous tone and return, capillary integrity and exchange, and microcirculatory flow help shape the fluid environment that supports healthy lymphatic function.*

Return

Venous tone and return

Supports healthy circulatory return.*

Diosmin + Hesperidin · 500 mg
Butcher’s Broom · 150 mg

Exchange

Capillary integrity and exchange

Supports healthy small-vessel exchange.*

Centella asiatica · 225 mg

Flow

Microcirculatory flow

Supports flow through the body’s smallest vessels.*

Grape Seed Extract · 200 mg

The shared outcome Healthy tissue-fluid balance*

Connected and overlapping, not sequential. These circulatory functions work alongside healthy lymphatic function.*

Every dose, disclosed

Not a proprietary blend.
Every active, every amount.

Five clinically studied actives in one daily serving — each named, fully disclosed, and included at a research-informed daily amount. This is the reason behind the way Lympha feels.

Four of five actives are standardized extracts with disclosed marker-compound targets. Butcher's Broom is included as a botanical extract within the formula.

What is Diosmin?

Diosmin is a citrus-derived bioflavonoid. In the most extensively studied human format for venous symptom burden and swelling-related outcomes, diosmin is used as part of a micronized purified flavonoid fraction (MPFF), typically described in a 9:1 diosmin–hesperidin ratio. Micronization is used in clinical MPFF preparations to improve dissolution characteristics and support consistent use in research protocols. Most of the strongest published human outcome data in this category therefore reflects a defined diosmin–hesperidin system rather than isolated diosmin alone. [1] [2]

Why it matters in Lympha's fluid-balance framework

Tissue fluid balance is shaped upstream by capillary filtration, venous tone, and microcirculatory conditions. When venous and microvascular function is less efficient, more fluid can remain in surrounding tissue - contributing to sensations such as heaviness, swelling, and lower-limb discomfort.

Human clinical research on MPFF commonly uses lower-limb venous models because they provide objective, quantifiable readouts of tissue fluid shift and symptom burden. In that context, MPFF is consistently associated with improvements in swelling proxies and reductions in common venous symptom scores. These are not direct measures of every aspect of lymphatic function, but they are clinically relevant indicators of the broader physiological environment in which tissue fluid handling occurs. [1] [2] [3]

Clinical evidence at a glance

Most human clinical evidence relevant to diosmin in this category comes from MPFF - a defined micronized diosmin + flavonoid system often described as 450 mg micronized diosmin + 50 mg flavonoids expressed as hesperidin. Across studies, outcomes are commonly assessed using objective circumference measures (ankle/calf), symptom scoring, quality-of-life instruments, and clinical severity measures. In clinical reviews and large real-world datasets, this evidence base frequently includes the Daflon 500 mg format, while some pooled swelling analyses report results at higher total daily MPFF doses (for example, 1000 mg/day). [1] [2] [3]

Swelling (objective proxies)

A systematic literature review and meta-analysis of prospective MPFF studies reports mean reductions in circumference of approximately 6.0 mm at the ankle and 5.7 mm at the calf at ~2 months, with sustained mean reductions of approximately 7.0 mm (ankle) and 6.7 mm (calf) at ≥6 months follow-up. These are modest absolute changes, but they are objective, repeatable measures commonly used in chronic venous disease research. Controlled trials summarized in clinical reviews also report improvements in swelling proxies and symptom measures versus placebo at the Daflon 500 mg MPFF format. [1] [2]

Ankle circumference: pooled analyses report mean reductions of approximately 6.0 mm at ~2 months and 7.0 mm at ≥6 months. [1]
Calf circumference: pooled analyses report mean reductions of approximately 5.7 mm at ~2 months and 6.7 mm at later follow-up. [1]

Symptoms + quality of life

Clinical reviews summarizing placebo-controlled trials report improvements in common venous symptom measures such as heaviness, discomfort or pain, cramps, and "feeling of swelling," alongside improved quality-of-life scores with Daflon 500 mg MPFF versus placebo. This combination of subjective and objective outcomes is one reason the diosmin–hesperidin literature remains the most established evidence base in this category. [2]

Heaviness + discomfort: improvements reported versus placebo in controlled trials using the Daflon 500 mg MPFF format. [2]
Cramps + leg comfort: improvements reported alongside symptom-score reduction and quality-of-life improvement in controlled trial summaries. [2]

Large-scale signal (real-world outcomes)

In a large multicountry prospective observational study, without a placebo control (RELIEF; n≈5,052), patients received MPFF over 6 months. Use was associated with progressive improvements in symptom scores and quality of life (CIVIQ), with edema assessed using leg circumference. This does not carry the same weight as a placebo-controlled trial, but it adds useful time-course and real-world breadth to the evidence base. [3]

Broader vascular-support context

Meta-analytic literature also reports benefit when MPFF is used as an adjunct in chronic venous ulcer care. This is not a lead consumer-facing endpoint for Lympha, but it strengthens the overall depth, durability, and clinical seriousness of the broader diosmin–hesperidin evidence base. [4]

Dose in Lympha

450 mg / day

Most-studied format

MPFF (9:1 with hesperidin)

Measured endpoints

Ankle/calf circumference, symptom scores, QoL, clinical severity indices

Primary actions

Venous comfort · microvascular function support · tissue fluid-balance context

Things to Know

The strongest body of human outcome data is reported for diosmin as part of MPFF (with hesperidin), not for isolated diosmin alone. [1] [2]
The literature includes placebo-controlled trials, large multicountry observational data, and broader meta-analytic context - not just one study type. [2] [3] [4]
Much of this evidence comes from chronic venous disease or insufficiency populations. Its relevance to Lympha's positioning is based on shared fluid-balance physiology, not on direct clinical trials of the finished formula. [1] [3]
Lympha mirrors the clinically common 9:1 diosmin–hesperidin ratio, although some published analyses also include higher total daily MPFF doses than the amount used in Lympha. [1] [2]

References

[1] Reduction of lower-limb edema in patients with chronic venous disease by micronized purified flavonoid fraction: systematic literature review and meta-analysis.
PubMed:38131655
[2] Daflon 500 mg: symptoms and edema clinical update.
PubMed:16193223
[3] Chronic venous insufficiency: worldwide results of the RELIEF study (Reflux assEssment and quaLity of lIfe improvEment with micronized Flavonoids).
PubMed:12025911
[4] Venous leg ulcer: a meta-analysis of adjunctive therapy with micronized purified flavonoid fraction.
PubMed:15936227

What is Hesperidin?

Hesperidin is a naturally occurring citrus flavonoid commonly used in vascular-support formulations. In the human clinical literature most relevant to venous symptom burden and swelling-related outcomes, it most frequently appears alongside diosmin as part of a defined flavonoid system rather than as a standalone intervention.

In Lympha, hesperidin is included to reflect the proportion used in the best-studied diosmin–hesperidin combinations, often described as micronized purified flavonoid fraction (MPFF). In that literature, outcomes are commonly evaluated using objective swelling proxies, symptom scoring, quality-of-life instruments, and clinical severity measures. Most of the strongest published human outcome data in this category therefore reflects the diosmin–hesperidin system as a whole, not isolated hesperidin alone. [1] [2] [3]

Why it matters in Lympha's fluid-balance framework

Tissue fluid balance is shaped upstream by capillary filtration, venous tone, and microcirculatory conditions. When microvascular permeability is higher or venous return is less efficient, more fluid can remain in tissues - contributing to sensations such as heaviness, swelling, and lower-limb discomfort.

As part of a clinically studied flavonoid system (MPFF), the diosmin–hesperidin combination is associated with support for venous function, symptom burden, and objective tissue fluid-balance proxies. These are not direct measures of every aspect of lymphatic function, but they are clinically relevant indicators of the broader physiological environment in which tissue fluid handling occurs. Clinical studies often use lower-limb venous models because fluid shifts are easiest to quantify there, even though the underlying physiology reflects a broader microvascular and fluid-balance context. [1] [2] [3]

Clinical evidence at a glance

Most human clinical evidence relevant to hesperidin in this category comes from MPFF — a defined diosmin + flavonoid system commonly described as 450 mg micronized diosmin + 50 mg flavonoids expressed as hesperidin. Across studies, outcomes are commonly assessed using objective circumference measures (ankle/calf), symptom scores, quality-of-life instruments, and clinical severity measures. This is why hesperidin is best interpreted within Lympha as part of a clinically informed flavonoid ratio rather than as a standalone hero ingredient. [1] [2] [3]

Swelling (objective proxies)

A systematic review and meta-analysis of prospective MPFF studies reports mean reductions in circumference of approximately 6.0 mm at the ankle and 5.7 mm at the calf at ~2 months, with sustained reductions of approximately 7.0 mm (ankle) and 6.7 mm (calf) at ≥6 months follow-up. Controlled trials at the 500 mg MPFF dose level also report improvements in objective swelling proxies and symptom measures versus placebo. [1] [2]

Ankle circumference: pooled analyses report mean reductions of approximately 6.0 mm at ~2 months and 7.0 mm at ≥6 months. [1]
Calf circumference: pooled analyses report mean reductions of approximately 5.7 mm at ~2 months and 6.7 mm at ≥6 months. [1]

Symptoms + quality of life

A clinical review summarizing placebo-controlled trials reports improvements in common venous symptom measures such as heaviness, discomfort or pain, cramps, and "feeling of swelling," alongside improved quality-of-life scores with MPFF versus placebo. Because hesperidin is part of that defined flavonoid system, this is the most relevant human evidence base for its role in Lympha. [2]

Heaviness + discomfort: improvements reported versus placebo in controlled trials using MPFF. [2]
Cramps + quality of life: improvements reported alongside symptom-score reduction and better quality-of-life measures in placebo-controlled trial summaries. [2]

Large-scale signal (real-world outcomes)

In a large multicountry prospective observational study, without a placebo control (RELIEF; n≈5,052), MPFF use over 6 months was associated with progressive improvements in symptom scores and quality of life (CIVIQ), with edema assessed using leg circumference. This does not carry the same weight as a placebo-controlled trial, but it adds useful time-course and real-world breadth to the evidence base. [3]

Broader vascular-support context

Meta-analytic literature also reports benefit when MPFF is used as an adjunct in chronic venous ulcer care. This is not a lead consumer-facing endpoint for hesperidin, but it strengthens the overall depth and durability of the broader diosmin–hesperidin evidence base. [4]

Dose in Lympha

50 mg / day

Clinical context

Paired with diosmin (9:1 ratio; MPFF model)

Measured endpoints

Ankle/calf circumference, symptom scores, QoL, clinical severity indices

Primary actions

Venous function support · tissue fluid-balance context · microvascular support (as part of MPFF system)

Things to Know

The strongest human outcome data is reported for hesperidin as part of the MPFF flavonoid system, not as isolated hesperidin alone. [1] [2]
Human outcomes in this literature are primarily measured using objective swelling proxies, symptom scores, quality-of-life instruments, and clinical severity measures. [1] [3]
Lympha uses hesperidin at the clinically common proportion reported in the most-studied 9:1 diosmin–flavonoid system. [2] [3]
Much of this evidence comes from chronic venous disease or insufficiency populations. Its relevance to Lympha's positioning is based on shared fluid-balance physiology, not on direct clinical trials of the finished formula. [1] [3]

References

[1] Reduction of lower-limb edema in patients with chronic venous disease by micronized purified flavonoid fraction: a systematic literature review and meta-analysis.
PubMed:38131655
[2] Daflon 500 mg: symptoms and edema clinical update.
PubMed:16193223
[3] Chronic venous insufficiency: worldwide results of the RELIEF study (Reflux assEssment and quaLity of lIfe improvEment with micronized Flavonoids).
PubMed:12025911
[4] Venous leg ulcer: a meta-analysis of adjunctive therapy with micronized purified flavonoid fraction.
PubMed:15936227

What is Grape Seed Extract?

Grape Seed Extract (GSE) is derived from Vitis vinifera seeds and standardized for oligomeric proanthocyanidins (OPCs), polyphenols studied in vascular and microcirculatory contexts.

In human research relevant to Lympha's formulation strategy, OPC-rich grape seed extracts have been evaluated using both objective and subjective endpoints - including leg swelling or volume measures under prolonged sitting, venous symptom and quality-of-life instruments in chronic venous disease populations, and more recently venous reflux-related measures in patients with varicose veins. The literature is directionally supportive, but study outcomes can vary by extract profile, dose, duration, and clinical model. [1] [2] [3]

Why it matters in Lympha's fluid-balance framework

Excess interstitial fluid often originates at the capillary and microvascular level. When microvascular barriers are less resilient or venous return is less efficient, more fluid can remain in tissues - contributing to temporary fluid accumulation, lower-limb discomfort, and a sensation of heaviness.

In human studies, OPC-rich grape seed extracts have been evaluated in models where tissue fluid shifts can be measured objectively, including prolonged sitting, as well as in chronic venous disease populations using symptom, severity, reflux, and quality-of-life instruments. These are not direct measures of every aspect of lymphatic function, but they are clinically relevant indicators of the broader physiological environment in which tissue fluid handling occurs. [1] [2] [3]

Clinical evidence at a glance

The evidence cited below includes three useful human models: (1) a placebo-controlled prolonged-sitting model in healthy women, (2) a randomized noninferiority trial versus MPFF in chronic venous disease, and (3) a newer randomized controlled trial evaluating venous reflux time, clinical severity, and quality of life in varicose-vein patients. Together, these studies help position grape seed extract as a clinically relevant microvascular and venous-support ingredient category, while still requiring caution around extract comparability and dose matching. [1] [2] [3]

Prolonged sitting model — double-blind placebo-controlled crossover (healthy women)

In a double-blind, placebo-controlled, crossover clinical study conducted in healthy Japanese women, both single-intake and 14-day intake trials were paired with a 6-hour sedentary sitting period after GSE or placebo administration. Measures of leg volume distension, body extracellular fluid, and leg water were reported as significantly suppressed in the GSE groups versus placebo. This is a useful model for acute fluid accumulation under sedentary strain, although it remains a single study in a relatively narrow population. [1]

Leg volume distension: reported as significantly suppressed versus placebo during the 6-hour sitting period. [1]
Fluid-related measures: increases in body extracellular fluid and leg water were also reported as significantly suppressed versus placebo. [1]

Chronic venous disease — randomized double-blind noninferiority trial (vs MPFF)

In a double-blind prospective randomized trial (n=303) enrolling patients with venous incompetence by duplex ultrasound (CEAP clinical class 1–3), Vitis vinifera seed extract was noninferior to MPFF for improving chronic venous disease quality of life (CIVIQ-20) at 8 weeks. In this context, "noninferior" means the difference between groups remained within a pre-specified acceptable margin; it does not mean the treatments were shown to be identical. Both groups improved from baseline, with no significant between-group difference in CIVIQ-20 change. The study used a specific Vitis vinifera seed extract formulation registered in Korea, so standardization and dose may differ from dietary supplement formats. [2]

Quality of life (CIVIQ-20): improved from baseline at 8 weeks in both groups; seed extract met the pre-specified noninferiority margin versus MPFF. [2]
Venous symptom and severity scales: AVVQ, VAS, and VCSS scores decreased at 4 and 8 weeks in both groups, without significant between-group differences. [2]
Leg circumference: calf circumference at 8 weeks was significantly reduced from baseline in the seed extract group; between-group circumference differences were not the primary outcome. [2]

Varicose-vein model — randomized controlled trial with reflux endpoint

In a more recent randomized controlled trial in adults with Doppler-confirmed varicose veins, grape seed extract given alongside lifestyle measures improved venous reflux time, venous clinical severity scoring, and disease-specific quality-of-life measures over 12 weeks versus lifestyle measures alone. This is an important addition because it introduces a more modern objective venous-function endpoint into the grape seed literature. The dose used in this study, however, was higher than the amount in Lympha. [3]

Venous reflux time: improved relative to the control condition over 12 weeks. [3]
Clinical severity + quality of life: VCSS and disease-specific QoL measures also improved with treatment. [3]
Dose context: the daily amount studied in this trial was higher than the 200 mg/day used in Lympha, so this should be interpreted as supportive category-level evidence rather than exact dose matching. [3]

Dose in Lympha

200 mg / day

Standardization

≥95% OPCs

Measured endpoints

Leg swelling / volume, venous reflux time, symptom scales, QoL

Role in system

Capillary integrity · venous function · fluid handling under strain

Things to Know

Human evidence includes a placebo-controlled prolonged-sitting model with objective measures of leg volume distension and fluid-related endpoints. [1]
Additional clinical evidence includes a randomized noninferiority trial versus MPFF in chronic venous disease and a newer randomized controlled trial evaluating venous reflux time in a varicose-vein population. [2] [3]
The literature is supportive but preparation-dependent; study outcomes can vary by extract format, standardization, dose, and population. [1] [2] [3]
Included in Lympha as a complementary OPC-rich polyphenol within a broader tissue fluid-balance system, not as a stand-alone claim anchor. [1] [2]

References

[1] Proanthocyanidin-rich grape seed extract reduces leg swelling in healthy women during prolonged sitting. J Sci Food Agric.
PubMed:22752876
[2] Vitis vinifera seed extract versus micronized purified flavonoid fraction for patients with chronic venous disease: a randomized noninferiority trial.
PubMed:39009117
[3] Vitis vinifera seed extract reduces venous reflux time in patients with varicose veins: VICTORY randomized controlled trial.
PubMed:41242464

What is Centella asiatica?

Centella asiatica is a medicinal plant whose primary bioactives are pentacyclic triterpenes, including asiaticoside, madecassoside, asiatic acid, and madecassic acid.

In human research, the strongest venous and microcirculatory evidence is tied to standardized triterpene fractions, often described as total or titrated triterpenic fractions such as TTFCA or TECA. These preparations have been evaluated in venous hypertension and venous microangiopathy using objective measures such as capillary filtration rate (CFR), microcirculatory flow, transcutaneous oxygenation metrics, venous distensibility, and leg volumetry. This is why Centella is best interpreted in Lympha as a standardized triterpene ingredient, not as a generic botanical. [1] [2] [3]

Why it matters in Lympha's fluid-balance framework

Tissue fluid balance depends heavily on the capillary–interstitial environment. When capillary filtration and microvascular leakage rise, more fluid can accumulate in tissues - contributing to heaviness, swelling-related discomfort, and a greater tissue fluid burden overall.

Standardized Centella triterpenes have been studied for capillary permeability parameters, microcirculatory function, and the broader exchange environment in which interstitial fluid movement occurs. These are not direct measures of every aspect of lymphatic function, but they are clinically relevant indicators of the upstream physiological context in which tissue fluid handling is shaped. [1] [2] [4]

Clinical evidence at a glance

Human trials in venous hypertension and venous insufficiency populations report improvements in swelling-related measures and objective microcirculatory endpoints with triterpene-standardized Centella extracts. A later systematic review also concluded that Centella may improve several microcirculatory and swelling-related parameters, while noting variation in study quality across the broader literature. [1] [2] [3] [4]

Capillary filtration rate (CFR) + ankle measures (4 weeks)

In a randomized, placebo-controlled, dose-ranging trial in patients with confirmed venous hypertension, Centella's total triterpenic fraction was evaluated over 4 weeks at doses of 90 mg/day and 180 mg/day, using CFR (assessed by venous occlusion plethysmography), ankle circumference, and an ankle edema tester. Greater improvements were observed at the higher dose. [1]

Capillary filtration rate (CFR): decreased after Centella treatment, with no significant change observed on placebo. [1]
Ankle measures: ankle circumference and edema-related measures improved alongside CFR at both doses; improvements were greater at 180 mg/day than at 90 mg/day. [1]

Microcirculation + tissue oxygenation + leg volumetry (6 weeks)

In a prospective randomized placebo-controlled study in venous microangiopathy or venous hypertension, Centella's total triterpenic fraction (120 mg/day) was assessed over 6 weeks using laser Doppler flow, transcutaneous gas metrics (O₂/CO₂), and leg volumetry. This is one of the most useful Centella studies because it includes objective physiologic endpoints beyond symptom scales alone. [2]

Leg volume: decreased by 66 mL (approximately 1.3%) after 6 weeks in the Centella group. [2]
Microcirculation + oxygenation endpoints: multiple parameters improved versus placebo, including transcutaneous O₂/CO₂ metrics. [2]

Symptoms + venous function (2 months)

In a multicenter, double-blind placebo-controlled trial over 2 months, TECA (titrated extract of Centella asiatica) at 60 mg/day and 120 mg/day was associated with improvements in heaviness and edema symptom ratings versus placebo at both doses. Venous distensibility, measured by strain-gauge plethysmography, improved in the TECA groups while worsening in the placebo group. The study is older, and its methodology reflects the standards of that period, but it remains relevant because it adds both symptom and vascular-function context. [3]

Systematic review context

A systematic review of human studies in chronic venous insufficiency concluded that Centella may improve several microcirculatory and swelling-related parameters, including transcutaneous gases, ankle swelling rate, and venoarteriolar response. This strengthens the case that Centella has a coherent human literature base in this category, while also making clear that risk of bias and reporting quality vary across studies. [4]

Dose in Lympha

225 mg / day (≈90 mg triterpenes)

Standardization

40% total triterpenes

Measured endpoints

CFR, ankle measures, microcirculatory flow, tissue oxygenation, leg volume, venous distensibility

Role in system

Capillary permeability · microcirculation · exchange environment

Things to Know

The most clinically relevant human evidence is tied to standardized triterpene fractions such as TTFCA and TECA, not generic Centella preparations. [1] [3]
Centella contributes a distinct type of evidence to the formula because human studies evaluate direct microcirculatory and capillary-filtration measures rather than relying only on symptom surveys. [1] [2]
The broader literature is coherent but not uniform. A systematic review supports Centella's relevance in this category while also noting that study quality varies. [4]
Lympha's triterpene output is directionally aligned with the standardized-triterpene literature, but not identical to every dose and trial format studied. [1] [2]

References

[1] Treatment of edema and increased capillary filtration in venous hypertension with total triterpenic fraction of Centella asiatica: a clinical, prospective, placebo-controlled, randomized, dose-ranging trial.
PubMed:11666125
[2] Microcirculatory effects of total triterpenic fraction of Centella asiatica in chronic venous hypertension: measurement by laser Doppler, TcPO₂-CO₂, and leg volumetry.
PubMed:11666123
[3] Titrated extract of Centella asiatica (TECA) in the treatment of venous insufficiency of the lower limbs.
PubMed:3544968
[4] A systematic review of the efficacy of Centella asiatica for improvement of the signs and symptoms of chronic venous insufficiency.
PubMed:23533507

What is Butcher's Broom?

Butcher's Broom (Ruscus aculeatus) is a traditional European botanical commonly used in venous-support settings and in products oriented around sensations such as heavy or tired legs. Its relevant phytochemistry is usually discussed in relation to ruscogenin-related compounds, and human studies have evaluated both Ruscus-containing single-preparation products and broader combination formulas.

In the literature most relevant to Lympha, Ruscus-based preparations are evaluated using objective swelling proxies such as leg volume and circumference, alongside symptom measures including heaviness, tension, and related lower-limb discomfort. The broader evidence base is clinically useful, but more preparation-dependent than the MPFF literature. [1] [2]

Why it matters in Lympha's fluid-balance framework

Tissue fluid balance is shaped upstream by venous tone, capillary permeability, and the broader microvascular environment. When venous function is less efficient and more fluid remains in surrounding tissue, sensations such as heaviness, tension, and lower-limb discomfort can become more noticeable.

In human studies, Ruscus-based preparations have been evaluated for objective swelling proxies and symptom burden in chronic venous insufficiency populations. These are not direct measures of every aspect of lymphatic function, but they are clinically relevant indicators of the broader physiological environment in which tissue fluid handling occurs. [1] [2] [3]

Clinical evidence at a glance

The evidence cited below includes a placebo-controlled clinical study in adults with chronic venous insufficiency, a meta-analysis of randomized double-blind placebo-controlled trials of Ruscus-containing venoactive preparations, and a secondary supportive study in an upper-limb lymphedema population using a combination product. Together, these sources support Ruscus as a clinically relevant venous-support ingredient category, while also showing that outcomes can vary by preparation type. [1] [2] [3]

Chronic venous insufficiency — placebo-controlled trial (12 weeks)

In a 12-week, randomized, double-blind, placebo-controlled clinical study in women with established chronic venous insufficiency (Widmer grade I–II), a proprietary Ruscus preparation reduced the integrated edema measure, corresponding to approximately ~827 mL·day less cumulative edema load versus placebo. The same study also reported favorable changes in lower-leg volume and symptom measures such as heavy or tired legs and tension. This is the cleanest direct trial in the drawer, but it still reflects a specific preparation rather than all forms of butcher's broom extract. [1]

Integrated edema over time: approximately ~827 mL·day less cumulative edema load versus placebo across the treatment period. [1]
Leg volume: average lower-leg volume was approximately ~20 mL lower versus placebo by week 12. [1]
Symptoms: heavy or tired legs and tension improved over 12 weeks, while placebo groups showed minimal change. [1]

Broader evidence base — meta-analysis of randomized placebo-controlled trials

A meta-analysis of randomized, double-blind, placebo-controlled trials found that Ruscus-containing venoactive preparations improved multiple symptom and edema-related outcomes, including pain, heaviness, feeling of swelling, ankle circumference, and lower-limb volume. This strengthens the overall evidence base meaningfully, although the included literature spans differing preparations and, in some cases, combination formulas rather than a single uniform extract format. [2]

Symptom burden: pooled evidence supports improvements in pain, heaviness, and feeling of swelling across the broader Ruscus-containing literature. [2]
Swelling proxies: ankle circumference and lower-limb volume also improved across pooled trial data. [2]

Secondary lymphedema model — supportive combination-product evidence

In a double-blind, placebo-controlled trial in women with secondary upper-limb lymphedema following breast cancer treatment, a combination product (CYCLO 3 FORT, containing Ruscus extract plus hesperidin methyl chalcone) produced a 12.9% reduction in arm edema volume after 3 months versus placebo. All participants also received manual lymphatic drainage. This is useful supportive context, but the effect reflects the combination product and study setting rather than Ruscus alone. [3]

Tolerability

Across placebo-controlled studies and broader pooled trial data, Ruscus-containing preparations were generally described as well tolerated, although tolerability findings still depend on the specific preparation studied. [1] [2]

Dose in Lympha

150 mg / day (10:1 extract)

Measured endpoints

Leg volume, ankle/calf circumference, heaviness, tension, symptom burden

Primary actions

Venous-support context · swelling proxies · leg comfort

Clinical context

Preparation-dependent human evidence in venous-support settings

Things to Know

The human literature supports Ruscus in venous-support contexts, but outcomes are more preparation-dependent than the MPFF literature. [1] [2]
Placebo-controlled human studies report improvements in swelling-related measures alongside better leg comfort over sustained use in chronic venous insufficiency populations. [1]
Broader meta-analytic evidence strengthens the case for Ruscus-containing preparations, while also making clear that formulation differences matter. [2]
Supportive evidence exists in a secondary lymphedema model using a combination product; those outcomes reflect the combination formula and study setting, not Ruscus alone. [3]
In Lympha, butcher's broom functions as the more venous-support-oriented component of the system, complementing the formula's flavonoid, polyphenol, and microcirculatory ingredients.

References

[1] Efficacy and safety of a Butcher's Broom (Ruscus aculeatus) preparation in patients with chronic venous insufficiency: double-blind, placebo-controlled clinical study.
PubMed:12040966
[2] Efficacy of Ruscus extract, HMC and vitamin C, constituents of Cyclo 3 fort®, on improving individual venous symptoms and edema: a systematic review and meta-analysis of randomized double-blind placebo-controlled trials.
PubMed:28225220
[3] Treatment of secondary lymphedema of the upper limb with CYCLO 3 FORT.
PubMed:8721977

From a practitioner

I recommend Lympha to clients between appointments because it’s one I use myself. I’ve experienced the benefits firsthand, and I appreciate that the formula is fully disclosed and made with standardized extracts. That transparency gives me confidence recommending it as part of a consistent daily routine.

How to use it

A 10-second ritual, easy to keep up

Four squeezes, once daily

Your full 4 mL dose — no pills. Most people fold it into a morning routine.
Into a tall glass of water or juice

A real botanical tincture, earthy by nature — 8 oz mellows the taste.
Stay consistent

Support builds gradually with daily use — a ritual, not a quick fix.

Verified customer reviews

Real experiences with Lympha

I travel often and my lower legs usually swell after flights, even when I wear compression socks. I have been taking this for a few weeks before my last trip and noticed a lot less swelling when I got home. Wish I had found this sooner!

My chiropractor recommended this after I mentioned the swelling I get in my lower legs and ankles. I’ve definitely noticed a difference since starting it!!

For the price I was skeptical it would be worth it. It is.

1 2

Questions, answered

How do I take it, and what does it taste like?

Measure 4 mL total using the marked dropper, or four 1 mL fills, and mix it into water or juice once daily. Morning or early afternoon works well for most routines. Lympha has a lightly sweet raspberry-vanilla flavor with an earthy botanical finish. Diluting it to taste softens the herbal notes. Shake well before each use, since the botanical ingredients naturally settle between servings. One bottle provides approximately 30 daily servings.

When should I assess how it is working for me?

Lympha is designed for consistent daily use rather than immediate water loss. We recommend taking it every day through your first bottle before assessing how it fits your routine. Published human research on the individual actives generally evaluated outcomes over several weeks or longer, and individual experiences vary.*

How is Lympha different from other lymphatic or circulation supplements?

Lympha is built around five named actives totaling 1,075 mg per daily serving. Every amount is disclosed, with no proprietary blend, and each amount was selected in reference to the published human evidence behind its ingredient or extract system. Every finished-product lot is potency tested for diosmin, hesperidin, proanthocyanidins, and triterpenes. The available research applies to the individual ingredients or related preparations, not the finished Lympha formula.*

Why a liquid instead of capsules?

A liquid allows the complete 1,075 mg active blend to fit into one measured daily serving without requiring multiple capsules. It is easy to add to water or juice and simple to keep consistent as part of a morning routine.

Does Lympha act as a diuretic or cause rapid water loss?

Lympha is not formulated or marketed as a diuretic and is not intended to force rapid water loss. It is designed to support the normal processes involved in healthy fluid balance, venous tone, microcirculatory flow, and lymphatic function.*

Can I take Lympha during perimenopause?

Lympha is not a hormone product and is not intended to address menopausal symptoms. It supports normal fluid balance, venous tone, microcirculatory flow, and healthy lymphatic function. If changes in your body are new, significant, or persistent, speak with your healthcare professional before assuming they are related to perimenopause.*

Who should speak with a healthcare professional before taking it?

Lympha is intended for adults. Do not use it while pregnant or nursing unless your healthcare professional advises otherwise. Consult a qualified healthcare professional before use if you take prescription medication, manage a medical condition, or are preparing for a procedure, particularly if you use medication that affects blood clotting or blood pressure. Discontinue use and seek guidance if you experience an adverse reaction.

Is it appropriate for ongoing daily use?

Lympha is intended for daily use as directed. The finished formula has not been independently studied for long-term continuous use, and published studies on its individual ingredients generally lasted weeks to months. If you plan to use it on an ongoing basis, particularly alongside medication or while managing a medical condition, review it with your healthcare professional.

When should swelling be evaluated by a healthcare professional?

New, unexplained, persistent, painful, red, hot, or one-sided swelling should be evaluated by a healthcare professional rather than self-managed with a supplement. Seek urgent medical attention for swelling accompanied by chest pain, shortness of breath, or difficulty breathing. Lympha is not intended to diagnose or treat the cause of swelling.

Begin with Lympha

Feel more like yourself,
one morning at a time.

A concentrated daily ritual for healthy fluid balance, built with five fully disclosed actives and backed by a 30-day money-back guarantee.

Your daily ritual

Daily serving: 4 mL once daily
Supply: 30 daily servings

Choose your plan

Free U.S. shipping Cancel anytime 30-day guarantee

Cart

Feel lighter. Less puffy. More like yourself.

You're not imagining it. Some days, your body feels slower to reset.

Puffy mornings

Desk days, travel days

Heavier by evening

Between bodywork sessions

Three connected circulatory functions behind healthy fluid balance.

Venous tone and return

Capillary integrity and exchange

Microcirculatory flow

Not a proprietary blend.
Every active, every amount.

A 10-second ritual, easy to keep up

Four squeezes, once daily

Into a tall glass of water or juice

Stay consistent

Real experiences with Lympha

Customer Reviews

Questions, answered

Feel more like yourself,
one morning at a time.

Cart

Feel lighter. Less puffy. More like yourself.

You're not imagining it. Some days, your body feels slower to reset.

Puffy mornings

Desk days, travel days

Heavier by evening

Between bodywork sessions

Venous tone and return

Capillary integrity and exchange

Microcirculatory flow

Not a proprietary blend.Every active, every amount.

A 10-second ritual, easy to keep up

Four squeezes, once daily

Into a tall glass of water or juice

Stay consistent

Real experiences with Lympha

Customer Reviews

Questions, answered

Feel more like yourself, one morning at a time.

Not a proprietary blend.
Every active, every amount.

Feel more like yourself,
one morning at a time.